<DOC>
	<DOCNO>NCT02820896</DOCNO>
	<brief_summary>This Phase I , randomize , placebo-controlled , double-blind study evaluate safety , tolerability , pharmacokinetics , preliminary activity RO7105705 two participant population : healthy participant participant mild-to-moderate Alzheimer 's disease . This study single dose , dose-escalation , multiple dose study comprise approximately six single dose cohort healthy participant administer RO7105705 , either intravenously ( IV ) subcutaneously ( SC ) , comprise one multiple dose cohort healthy participant administer RO7105705 IV every week ( QW ) , total 4 dos , one multiple dose cohort participant Alzheimer 's disease administer RO7105705 IV QW , total 4 dos .</brief_summary>
	<brief_title>A Study RO7105705 Healthy Participants Participants With Mild-to-Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>All participant Total body weight 45 120 kilogram ( kg ) , inclusive Agreement donate blood blood product transfusion duration study 1 year final dose study drug In good health , determine clinically significant finding medical history , physical examination , 12lead electrocardiogram ( ECG ) , laboratory test , vital sign Clinical laboratory evaluation ( include chemistry panel fast [ fast least 8 hour ] , complete blood count ( CBC ) , urine analysis ) within reference range test laboratory , unless deem clinically significant investigator Negative test select drug abuse screen checkin Agreement use highly effective contraception measure Healthy Participants Ages 1880 year inclusive No history symptomatic cognitive decline concern clinically significant cognitive impairment participant investigator Participants enroll cohort require lumbar puncture No contraindication lumbar dural puncture , include coagulopathy , concomitant anticoagulation , thrombocytopenia , prior lumbar spinal surgery , factor precludes safe lumbar puncture opinion investigator Participants Alzheimer 's disease Ages 5080 year , inclusive The participant capable complete assessment either alone help caregiver Availability person ( caregiver ) , investigator 's judgment , frequent sufficient contact participant able provide accurate information regard participant 's cognitive functional ability , agree provide information clinic visit , require partner input scale completion , sign necessary consent form Adequate visual auditory acuity , investigator 's judgment , sufficient perform neuropsychological test Clinical diagnosis probable Alzheimer 's disease dementia base National Institute AgingAlzheimer 's Association criterion Screening minimental state examination ( MMSE ) score 1628 point , inclusive Screening Clinical Dementia RatingGlobal Score ( CDRGS ) 0.5 , 1.0 , 2.0 Positive florbetapir amyloid positron emission tomography ( PET ) scan qualitative read If already take cholinesterase inhibitor and/or memantine therapy Alzheimer 's disease , stable dose least 4 week prior screen . There intent , discontinue , alter dose Alzheimer 's disease therapy duration study Any participant Pregnant lactating , intend become pregnant within 16 week last dose study drug Participation clinical trial within 30 day randomization ; use experimental oral therapy within 30 day 5 halflives prior Day 1 , whichever great ; use biologic therapy within 12 week 5 halflives prior Day 1 , whichever great Any nonexperimental vaccine within 2 week randomization , 2 week last dose Surgery hospitalization 4 week prior screen Planned procedure surgery study Blood transfusion within 8 week prior screen Donation loss blood ( exclude volume blood drawn screen procedure ) follow : 50499 milliliter ( mL ) blood within 30 day great ( &gt; ) 499 mL blood within 56 day prior study drug administration Poor peripheral venous access Positive hepatitis C virus ( HCV ) antibody , hepatitis B surface antigen ( HBsAg ) , human immunodeficiency virus ( HIV ) antibody Illicit drug alcohol abuse within 12 month prior screen , investigator 's judgment Administration herbal nutritional supplement ( exception standard vitamin calcium supplement ) within 7 day prior study dose Past history seizure , prior traumatic brain injury , schizophrenia , schizoaffective disorder , bipolar disorder At risk suicide opinion investigator Serious infection require oral IV antibiotic within 30 day prior screen Any serious medical condition abnormality clinical laboratory test ; systemically , clinically immunocompromised continue effect immunesuppressing medication Participants Alzheimer 's disease History presence clinically evident vascular disease potentially affect brain History presence stroke within previous 2 year document history transient ischemic attack within previous 12 month History presence intracranial tumor clinically relevant opinion investigator Presence infection affect brain function history infection result neurologic sequelae History presence central nervous system ( CNS ) systemic autoimmune disorder potentially cause progressive neurologic disease associate cognitive deficit History presence neurologic disease Alzheimer 's disease may affect cognition Magnetic resonance imaging ( MRI ) evidence 1 ) two lacunar infarct , 2 ) territorial infarct le ( &gt; ) 1 centimeter ( cm ) , 3 ) significant fluid attenuate inversion recovery ( FLAIR ) hyperintense lesion cerebral white matter may , investigator 's opinion , contribute cognitive dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>